title: Daylight photodynamic therapy with MAL cream for large-scale photodamaged skin based on the concept of 'actinic field damage': recommendations of an international expert group.
abstract: Conventional PDT (c-PDT) is a widely used and approved non-invasive treatment for actinic keratosis (AK). Recent clinical, histological and immunohistochemical observations have shown that c-PDT with methyl aminolevulinate (MAL) may also partially reverse the signs of photodamage. However, pain and the need for special light source equipment are limiting factors for its use, especially in the treatment of large areas. More recently, daylight PDT (DL-PDT) has been shown to be similar to c-PDT in the treatment of AK, nearly painless and more convenient to perform. To establish consensus on recommendations for the use of MAL DL-PDT in patients with large-scale photodamaged skin. The expert group was comprised of eight dermatologists. Consensus was developed based on the personal experience of the experts in c-PDT and DL-PDT, and results of an extensive literature review. MAL DL-PDT for large areas of photodamaged skin was evaluated and recommendations based on broad clinical experience were provided. As supported by evidence-based data from multicentre studies conducted in Australia and Europe, the authors defined the concept of 'actinic field damage' which refers to photodamage associated with actinic epidermal dysplasia, and provide comprehensive guidelines for the optimal use of DL-PDT in the treatment of actinic field damage. The authors concluded that MAL DL-PDT has a similar efficacy to c-PDT at 3-month (lesion complete response rate of 89% vs. 93% in the Australian study and 70% vs. 74% in the European study (95% C.I. = [-6.8;-0.3] and [-9.5;2.4] respectively) and 6-month follow-ups (97% maintenance of complete lesion response) in the treatment of AKs. The authors agree that DL-PDT is not only efficacious but also nearly pain-free and easy to perform, and therefore results in high patient acceptance especially for the treatment of areas of actinic field damage.
authors.affiliation: Hautzentrum Koeln (Cologne Dermatology), Cologne, Germany.
authors.forename: W G
authors.initials: WG
authors.lastname: Philipp-Dormston
authors.affiliation: Group of Investigative Dermatology (GRID), School of Medicine, University of Antioquia, Medellín, Colombia.
authors.forename: G
authors.initials: G
authors.lastname: Sanclemente
authors.affiliation: Faculty of Medicine, Hospital das Clinicas, Universidade de Sao Paulo, Sao Paulo, Brazil.
authors.forename: L
authors.initials: L
authors.lastname: Torezan
authors.affiliation: Plastic Surgery, Instituto Dermatologico Europeo, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Tretti Clementoni
authors.affiliation: Service de Dermatologie, Hôpital Privé Clairval, Marseille, France.
authors.forename: A
authors.initials: A
authors.lastname: Le Pillouer-Prost
authors.affiliation: Centre Medical Saint Jean, Arras, France.
authors.forename: H
authors.initials: H
authors.lastname: Cartier
authors.affiliation: Department of Dermatology and Allergology, Vest Clinic, Recklinghausen, Germany.
authors.forename: R M
authors.initials: RM
authors.lastname: Szeimies
authors.affiliation: Department of Dermatology, Molholm Hospital, Vejle, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Bjerring
mesh_terms: D000287:Administration, Topical; D000622:Aminolevulinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D032921:Consensus; D005060:Europe; D006801:Humans; D055623:Keratosis, Actinic / Q000188:drug therapy*; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*
chemical_list: D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid